ArticleAtherosclerosis2026
Sex-based differences in cardiovascular risk management and abdominal aortic aneurysm growth: Insights from a contemporary cohort study.
Article in Atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAlthough abdominal aortic aneurysms (AAA) are more prevalent in men, women experience more unpredictable AAA growth and rupture risk, and higher mortality. This study aimed to compare sex differences in cardiovascular risk reducing strategies and AAA outcomes.
methodsAnnualized AAA growth rates and outcomes were assessed over a 10-year period in patients with at least two aortic duplex studies. We compared baseline demographics and prescribing patterns between men and women. Variables associated with fast AAA growth (≥0.5 cm/year) were identified using backward selection, and analyses were stratified by sex.
resultsOf the 2008 patients included in this analysis, 20.0% were women. Women had higher systolic blood pressures, higher rates of smoking, and were less likely to be prescribed Statins or angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs). No significant difference was observed between men and women in the rates of rapid growth, dissection, rupture, repair, or all-cause mortality. While there were no sex-specific differences in the variables included in our final model (aspirin, metformin, coronary artery disease, smoking, and hypertension), ACEi/ARBs were associated with lower odds of fast AAA growth in women but not men, indicating a sex-specific interaction.
conclusionWhile we did not identify differences in AAA outcomes, our findings reveal a disparity in the application of cardiovascular risk reducing strategies between men and women. The observed association between ACEi/ARB use and slower growth in women, but not in men, warrants further investigation. These results underscore the need for more targeted and equitable cardiovascular risk management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.